Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yonghe Medical Group CoSTU:L97 -5.97%84 EBITDA Margin % is 12.50% as of Jun. 2026, which is 36% below its 10-year median of 19.60. GuruFocus rates STU:L97 with a GF Score™ of 84/100 and a GF Value™ of €0.20. The stock has 7 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Yonghe Medical Group Co ranks worse than 56.02% on this metric.
Yonghe Medical Group Co (STU:L97) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Yonghe Medical Group Co EBITDA Margin % Related Terms
Yonghe Medical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L97 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Yonghe Medical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yonghe Medical Group Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yonghe Medical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Yonghe Medical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yonghe Medical Group Co (STU:L97) has a EBITDA Margin % of 12.50% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Yonghe Medical Group Co and its competitors. This is 36% below median its historical median of 19.60. According to the industry distribution chart, Yonghe Medical Group Co ranks #372 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 56%.
Is Yonghe Medical Group Co's EBITDA Margin % too high?
Yonghe Medical Group Co's current EBITDA Margin % of 12.50% is 36% below median its 10-year median of 19.60. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Yonghe Medical Group Co's value of 12.50% is 22.1% above this industry median. Based on the distribution chart, Yonghe Medical Group Co ranks #372 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Yonghe Medical Group Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Yonghe Medical Group Co's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Yonghe Medical Group Co ranks #372 out of 664 companies for EBITDA Margin %. This places Yonghe Medical Group Co in the lower half of its industry. The industry median EBITDA Margin % is 10.24. Yonghe Medical Group Co's value of 12.50% is 22.1% above this benchmark. While the company's 10-year median is 19.60 vs. the industry median of 10.24, Yonghe Medical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yonghe Medical Group Co's current EBITDA Margin % of 12.50% is 22.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Yonghe Medical Group Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yonghe Medical Group Co's current EBITDA Margin % is 12.50%, which is 36% below median its own 10-year median of 19.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yonghe Medical Group Co stock overvalued right now?
Yonghe Medical Group Co (STU:L97) has a current EBITDA Margin % of 12.50%. The stock's GF Value™ is €0.20, compared to a current price of €0.25 — trading 26% above its estimated fair value. The current EBITDA Margin % is 12.50%, which is 36% below median its 10-year median of 19.60 and 22.1% above the Healthcare Providers & Services industry median of 10.24. Yonghe Medical Group Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Yonghe Medical Group Co (STU:L97), the current EBITDA Margin % is 12.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yonghe Medical Group Co (STU:L97) Overvalued in 2026?
Based on GuruFocus' analysis, Yonghe Medical Group Co stock appears to be overvalued.
The current stock price of €0.25 is trading 26% above its estimated GF Value™ of €0.20.
Key valuation signals for STU:L97:
EBITDA Margin %: 12.50% (36% below median its 10-year median of 19.60)
GF Value™: €0.20 vs. price of €0.25 (26% above fair value)
Industry Position: 22.1% above the Healthcare Providers & Services median (#372 of 664)
No single metric tells the full story. See the STU:L97 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yonghe Medical Group Co Ltd is a medical group in China that specializes in providing hair-related healthcare services. The company is principally engaged in the provision of hair transplant services. The company generated the majority of its revenue from hair transplant services. The company offers one-stop hair-related healthcare services covering hair transplants, medical hair care, routine hair restoration, and other ancillary services.
84GF Score
Get the complete analysis for STU:L97
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L97 has been successfully added to your 
